2Q preview: GSK, Biogen Idec, Gilead, Roche, Lilly, BMS, Celgene
This article was originally published in Scrip
Executive Summary
Johnson & Johnson kicked off the second-quarter earnings season with a 21.1% year-over-year increase in its pharma sales to $8.5bn, setting a high bar for companies yet to report their earnings (scripintelligence.com, 16 July 2014).